SGLT2 inhibitors

Dapagliflozin - Empagliflozin      

Select
Display
Trial Studied trt Control trt patientstagsNCTROB Result

diabetes type 2

canagliflozin
3005: monotherapy ongoing canagliflozinplacebo ongoing
CANTATA-D ongoing canagliflozinplacebo (add-on MET)NCT01106677 ongoing
3009: Add-on to MET ongoing canagliflozinplacebo (add-on MET) ongoing
3008: Add-on to insulin ongoing canagliflozinplacebo (add-on MET) ongoing
3015: Add-on to MET + SU ongoing canagliflozinplacebo (add-on MET+SU) ongoing
3002: Add-on to MET + SU ongoing canagliflozinplacebo (add-on MET+SU) ongoing
3012: Add-on to MET +TZD ongoing canagliflozinplacebo (add-on MET+TZD) ongoing
3008: Add-on to SU ongoing canagliflozinplacebo (add-on SU) ongoing
dapagliflozin
Yang, 2015dapagliflozinNCT01095666 -
D1695C00001 ongoing dapagliflozindapagliflozinNCT02582814 ongoing
Nauck, 2011dapagliflozindlipizide add on metforminNCT00660907 -
CV181-369 ongoing Saxagliptin/DapagliflozinGlargine insulinNCT02551874 ongoing
Ferrannini (MB102013), 2010dapagliflozinplaceboNCT00528372 -
Komoroski (MB102007), 2009dapagliflozinplaceboNCT00162305Exploratory -
List (MB102008), 2009dapagliflozinplaceboNCT00263276Exploratory -
KOhandapagliflozinplaceboNCT00736879Low risk of bias -
KohandapagliflozinplaceboNCT00663260 -
KohandapagliflozinplaceboNCT00972244 -
Kaku, 2014dapagliflozinplaceboNCT01294423 -
DERIVE ongoing dapagliflozinplaceboNCT02413398 ongoing
MB102-210 ongoing dapagliflozinplaceboNCT02383238 ongoing
DECLARE-TIMI 58 ongoing dapagliflozinplaceboNCT01730534 ongoing
D1693C00002 ongoing dapagliflozinplaceboNCT01257412 ongoing
D1690C00023 ongoing dapagliflozinplaceboNCT02547935 ongoing
D5553C00003 ongoing dapagliflozinplacebo (add on EXE)NCT02229396 ongoing
MB102-137 ongoing dapagliflozinplacebo (add on INS)NCT02096705 ongoing
Wilding (MB102009), 2009dapagliflozinplacebo (add on insulin)NCT00357370 -
Wilding, 2012dapagliflozinplacebo (add on insulin)NCT00673231 -
Mathieu, 2015dapagliflozinplacebo (add on MET + SAXA)NCT01646320 -
Bailey (MB102014), 2010dapagliflozinplacebo (add on MET)NCT00528879Exploratory -
Bolinder, 2012dapagliflozinplacebo (add on MET)NCT00855166 -
Schumm-Draeger , 2015dapagliflozinplacebo (add on MET)NCT01217892 -
Matthaei, 2015dapagliflozinplacebo (add on MET+SU)NCT01392677 -
D1683C00005 ongoing dapagliflozinplacebo (add on SAXA + MET)NCT02681094 ongoing
Rosenstock, 2012dapagliflozinplacebo (add on TZD)NCT00683878 -
MB102-054 ongoing dapagliflozinplacebo (add-on MET)NCT01095653 ongoing
MB102035dapagliflozinplacebo (on top standard treatment)NCT00976495 -
Cefalu, 2015dapagliflozinplacebo (on top standard treatment)NCT01031680 -
Leiter, 2016dapagliflozinplacebo (on top standard treatment)NCT01042977 -
MB102073dapagliflozinplacebo (on top standard treatment)NCT01137474 -
Weberdapagliflozinplacebo (on top standard treatment)NCT01195662 -
MB102061dapagliflozinplacebo add on DPP-4NCT00984867 -
CV181-363 ongoing dapagliflozinsaxa (add on MET)NCT02284893 ongoing
Rosenstock, 2015dapagliflozinSaxagliptin (add on MET)NCT01606007 -
CV181-365 ongoing dapagliflozinSaxagliptin (add on MET)NCT02419612 ongoing
0431-838 ongoing dapagliflozinSitagliptin (add on mET)NCT02532855 ongoing
Kohandapagliflozin + merformindapagliflozinNCT00643851 -
Strojek, 2011dapagliflozin + GlimepirideglimepirideNCT00680745 -
MB102034, 2016dapagliflozin + merforminmetformin or dapaNCT00859898 -
empagliflozin
Kadowaki, 2013empagliflozin -
Kadowaki , 2014empagliflozin -
1275.9 ongoing empagliflozinadd-on linagliptin + METNCT01734785 ongoing
Ridderstrale, 2014empagliflozinGlimepiride + METNCT01167881 -
DeFronzo, 2015empagliflozinlinagliptin (add-on MET)NCT01422876 -
Lewin, 2015empagliflozinlinagliptin (monotherapy)NCT01422876 -
1276.1 (bitherapy MET) ongoing empagliflozin + METMETNCT01719003 ongoing
EMPA-REG OUTCOMEempagliflozinplaceboNCT01131676 -
Barnett, 2014empagliflozinplaceboNCT01164501 -
Ferrannini, 2013empagliflozinplaceboNCT00789035 -
EMPA-REG MONO (Roden) vs placebo, 2013empagliflozinplaceboNCT01177813 -
Kadowaki, 2015empagliflozinplaceboNCT01193218 -
1245.29 ongoing empagliflozinplaceboNCT02182830 ongoing
EMPA-REG PIO (Kovacs), 2013empagliflozinplacebo (add on MET+/-PIO)NCT01210001 -
99050 ongoing empagliflozinplacebo (add on MET+/-SU)NCT01257334 ongoing
Rosenstock DOUBLON ???, 2013empagliflozinplacebo (add-on INS) -
EASE-2 ongoing empagliflozinPlacebo (add-on INS)NCT02414958 ongoing
Rosenstock (1245.49), 2014empagliflozinplacebo (add-on INS+/-MET)NCT01306214 -
Rosenstock, 2013empagliflozinplacebo (add-on MET)NCT00749190 -
Ross, 2015empagliflozinplacebo (add-on MET)e2012-000905-53 -
EMPA-REG MET (Haring), 2014empagliflozinplacebo (add-on MET)NCT01159600 -
Araki, 2015empagliflozinplacebo (add-on standard treatment)NCT01368081 -
1275.19 ongoing empagliflozinplacebo add-on linagliptinNCT02453555 ongoing